Stryker Corporation (NYSE:SYK) has been given a $160.00 target price by analysts at Cowen and Company in a report released on Friday. The brokerage presently has a “buy” rating on the medical technology company’s stock. Cowen and Company’s target price would indicate a potential upside of 7.38% from the company’s current price.

A number of other brokerages have also weighed in on SYK. BMO Capital Markets reaffirmed a “hold” rating and issued a $140.00 price target on shares of Stryker Corporation in a research note on Tuesday, July 11th. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Stryker Corporation in a research note on Monday, June 19th. Citigroup Inc. lifted their price target on shares of Stryker Corporation from $114.00 to $125.00 and gave the company a “sell” rating in a research note on Friday, June 9th. Cantor Fitzgerald initiated coverage on shares of Stryker Corporation in a research note on Thursday, June 29th. They issued a “neutral” rating and a $153.00 price target on the stock. Finally, Morgan Stanley reissued an “overweight” rating and issued a $160.00 price objective (up previously from $155.00) on shares of Stryker Corporation in a research report on Monday, July 10th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $146.78.

Stryker Corporation (NYSE:SYK) traded up 0.47% on Friday, reaching $149.00. 1,129,048 shares of the company’s stock traded hands. The stock’s 50 day moving average is $142.34 and its 200 day moving average is $139.87. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $149.23. The firm has a market cap of $55.74 billion, a price-to-earnings ratio of 33.26 and a beta of 0.80.

Stryker Corporation (NYSE:SYK) last announced its quarterly earnings results on Thursday, July 27th. The medical technology company reported $1.53 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.51 by $0.02. Stryker Corporation had a net margin of 14.22% and a return on equity of 24.26%. The firm had revenue of $3.01 billion for the quarter, compared to analyst estimates of $2.98 billion. During the same quarter in the previous year, the firm posted $1.39 earnings per share. The business’s revenue was up 6.1% on a year-over-year basis. On average, equities research analysts predict that Stryker Corporation will post $6.46 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Stryker Corporation (SYK) Given a $160.00 Price Target by Cowen and Company Analysts” was originally reported by Watch List News and is the sole property of of Watch List News. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.watchlistnews.com/stryker-corporation-syk-given-a-160-00-price-target-by-cowen-and-company-analysts/1613650.html.

In other Stryker Corporation news, insider David Floyd sold 19,305 shares of the company’s stock in a transaction on Wednesday, July 12th. The shares were sold at an average price of $144.56, for a total value of $2,790,730.80. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Lonny J. Carpenter sold 5,000 shares of the company’s stock in a transaction on Friday, August 4th. The shares were sold at an average price of $146.36, for a total transaction of $731,800.00. Following the completion of the transaction, the insider now owns 88,207 shares in the company, valued at $12,909,976.52. The disclosure for this sale can be found here. Over the last quarter, insiders sold 25,429 shares of company stock worth $3,686,927. Corporate insiders own 7.40% of the company’s stock.

Several institutional investors have recently made changes to their positions in SYK. BlackRock Inc. boosted its position in shares of Stryker Corporation by 2,526.4% in the first quarter. BlackRock Inc. now owns 21,976,771 shares of the medical technology company’s stock valued at $2,893,242,000 after acquiring an additional 21,140,000 shares during the period. Koch Industries Inc. boosted its position in shares of Stryker Corporation by 34,120.3% in the second quarter. Koch Industries Inc. now owns 1,260,675 shares of the medical technology company’s stock valued at $1,252,000 after acquiring an additional 1,256,991 shares during the period. Vanguard Group Inc. boosted its position in shares of Stryker Corporation by 5.2% in the first quarter. Vanguard Group Inc. now owns 23,421,053 shares of the medical technology company’s stock valued at $3,083,382,000 after acquiring an additional 1,161,688 shares during the period. Janus Henderson Group PLC boosted its position in shares of Stryker Corporation by 2,237.8% in the second quarter. Janus Henderson Group PLC now owns 1,019,254 shares of the medical technology company’s stock valued at $141,452,000 after acquiring an additional 975,656 shares during the period. Finally, PNC Financial Services Group Inc. boosted its position in shares of Stryker Corporation by 41.9% in the first quarter. PNC Financial Services Group Inc. now owns 1,403,420 shares of the medical technology company’s stock valued at $184,759,000 after acquiring an additional 414,715 shares during the period. 74.13% of the stock is owned by institutional investors.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.